Intrinsic Value

The intrinsic value of Genomtec SA (4VI) under the Base Case is 0.078 EUR per share. Compared with the current market price of 0.494 EUR, the stock appears Overvalued by 84% .

The intrinsic value is calculated using the DCF method.

Do our valuations actually work? See backtest results .

4VI Intrinsic Value
€0.078
Overvaluation 84%
Intrinsic Value
Price €0.494
Alert me when 4VI is below its intrinsic value
Today €0.063 · 87.3% below the current price

4VI is cheaper than usual. Still overvalued, but less so than on 82% of days in the past 5 years.

Alternatives to 4VI

Fundamental Analysis

What Genomtec Does

Genomtec is a Polish life-science company that develops molecular diagnostics tools for detecting genetic material from pathogens and other biological samples. Its core work centers on laboratory and point-of-care testing systems, including the test cartridges and instruments needed to run them. The company sells its technology into healthcare and diagnostics, where fast and accurate identification of infections matters.

Headquarters
Poland PL
IPO date
Mar 17, 2021
Read the full company overview
View Company Overview
Financials

Balance Sheet

Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Recent Events

Past 12 months

Continue 4VI Research

Decided on Genomtec? Get an email when 4VI reaches the price you’d buy at. Free with an account.

Other Genomtec listings

What is the Intrinsic Value of one 4VI stock?

The intrinsic value for Genomtec SA (4VI) under the Base Case is 0.078 EUR.

Is 4VI stock undervalued or overvalued?

Compared with the current market price of 0.494 EUR, the stock appears Overvalued by 84% .

How reliable are our estimates? See how past valuations played out
Back to Top